Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL

BACKGROUND: Dose escalation and modification of CHOP has improved the prognosis of patients with aggressive lymphoma; even in the rituximab era, dose escalation for high-risk patients is exploited and frequently limited by drug toxicity. Idarubicin (Id) is a 4-demethoxy anthracycline analogue of dau...

Descripción completa

Detalles Bibliográficos
Autores principales: Hohloch, Karin, Zwick, Carsten, Ziepert, Marita, Hasenclever, Dirk, Kaiser, Ulrich, Engert, Andreas, Höffkes, Heinz-Gert, Kroschinsky, Frank, Mesters, Rolf, Feller, Andreas C, Löffler, Markus, Trümper, Lorenz, Pfreundschuh, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890437/
https://www.ncbi.nlm.nih.gov/pubmed/24455463
http://dx.doi.org/10.1186/2193-1801-3-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890437/
https://www.ncbi.nlm.nih.gov/pubmed/24455463
http://dx.doi.org/10.1186/2193-1801-3-5

Ejemplares similares